Shionogi & Co. Ltd.

http://www.shionogi.co.jp/index.html

Already a Biomedtracker subscriber? You have access to the full company record through your subscription

Want to become a subscriber? Subscribers get more company details, updates, company financials and company products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Bookmark

17 May 2022
News

By Joseph Haas, Jung Won Shin and Dexter Yan

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

Deal Watch Business Strategies

Finance Watch: HilleVax, Belite Bio Launch First Two Biopharma IPOs In Q2

Bookmark

29 Apr 2022
Analysis

By Mandy Jackson and Kevin Grogan

Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.

Financing Innovation

Japan Progresses 'Urgent Approval' System To Speed Drug Access

Bookmark

20 Apr 2022
Analysis

By Lisa Takagi

Japan is intending to revise existing pharma legislation to enable the urgent approval of new drugs with "assumed efficacy", with a maximum three-year period for confirmation, in cases of emergency need. The government will also ask companies to implement tighter safety monitoring and management of supply chains, with swift data disclosure required, as part of the planned changes.

Japan Drug Approval Standards